Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Golden

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
American Family Physician|January 23, 2023
Medical Methods for First-Trimester AbortionDonna Cohen, Lisa Golden
Journal of Public Health Management and Practice : JPHMP|May 14, 2015
Increasing Colorectal Cancer Screening at Community-Based Primary Care Clinics in San FranciscoRani Marx, Winnie M Tse, Lisa Golden, et al.
Journal of the American Geriatrics Society|January 7, 2021
Early COVID-19 Successes in Skilled Nursing Facilities in San FranciscoJanice K Louie, Juliet Stoltey, Hyman M Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerDavid Hong, Jeffrey Infante, Filip Janku, et al.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
American Family Physician|January 23, 2023
Medical Methods for First-Trimester AbortionDonna Cohen, Lisa Golden
Journal of Public Health Management and Practice : JPHMP|May 14, 2015
Increasing Colorectal Cancer Screening at Community-Based Primary Care Clinics in San FranciscoRani Marx, Winnie M Tse, Lisa Golden, et al.
Journal of the American Geriatrics Society|January 7, 2021
Early COVID-19 Successes in Skilled Nursing Facilities in San FranciscoJanice K Louie, Juliet Stoltey, Hyman M Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced CancerDavid Hong, Jeffrey Infante, Filip Janku, et al.
Gynecologic Oncology|December 4, 2019
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancerIgnace Vergote, Florian Heitz, Paul Buderath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2018
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell CarcinomaDavid S Hong, Kathleen Moore, Manish Patel, et al.
Pageof 1